Retinopathy held a 29.7% share of the ophthalmic clinical trials market in 2025, making it the leading indication segment. Its leadership is supported by the sustained volume of clinical development tied to diabetic eye disease and related retinal complications, where treatment evaluation often requires structured, long-duration studies with clearly defined ophthalmic endpoints. That steady pipeline activity helps retinopathy maintain a strong share position in the ophthalmic clinical trials market, as sponsors continue to focus on conditions with established diagnostic pathways and significant ongoing trial demand.

Glaucoma is emerging as the fastest-growing indication in the ophthalmic clinical trials market as development activity increasingly centers on therapies and intervention approaches aimed at preserving vision through earlier and more consistent disease control. Growth is gaining pace because glaucoma presents practical unmet trial needs around long-term management, intraocular pressure control, and treatment adherence, creating room for newer clinical strategies relative to more established indication areas. This momentum is helping glaucoma outpace alternatives as sponsors seek differentiated outcomes in a condition with persistent monitoring and progression challenges.

Product Segment Analysis: Drugs (Largest Segment) vs Devices (Fastest-Growing Segment)

By 2025, drugs accounted for the largest share of the ophthalmic clinical trials market. This position is sustained by the broad use of pharmaceutical approaches across multiple ophthalmic indications, where trial designs, dosing evaluation, safety monitoring, and efficacy assessment are well established within clinical development pathways. The depth of ongoing drug-based research keeps this product segment at the center of the ophthalmic clinical trials market, especially where sponsors rely on familiar regulatory and operational models to advance candidates across diverse eye disorders.

Devices are the fastest-growing product segment in the ophthalmic clinical trials market, encouraged by rising development interest in intervention-based treatment options that address limitations of conventional therapeutic delivery and disease management. Their momentum is strengthening because device trials are increasingly aligned with practical clinical needs such as procedural precision, sustained treatment effect, and targeted ocular application, which can offer a differentiated route compared with drug-only approaches. As a result, devices are attracting growing trial activity where innovation depends on treatment administration and performance in real-world ophthalmic care settings.